Treatment for Hormone-Refractory Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Hormone-Refractory Prostate Cancer
Eligibility
18 - 90
Male
What conditions do you have?
Select

Study Summary

This trial finds that MRI-guided prostate SBRT is safe for patients with metastatic prostate cancer, with similar quality of life outcomes to those without metastatic prostate cancer.

Eligible Conditions
  • Hormone-Refractory Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: baseline, 3-6months and at 9-12 months.

Month 12
Change in Number of Subjects with Adverse events will be collected
Change in Quality of life questionnaires will be assessed.
Change in The International Prostate Symptom Score (I-PSS) will be assessed.

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

20 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 1

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 3-6months and at 9-12 months.

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
986 Previous Clinical Trials
1,338,485 Total Patients Enrolled
Josephine Kang, M.D.,Ph.D.Principal InvestigatorWeill Medical College of Cornell University
1 Previous Clinical Trials
50 Total Patients Enrolled
Ariel Marciscano, M.D.Principal InvestigatorWeill Medical College of Cornell University
1 Previous Clinical Trials
50 Total Patients Enrolled

Eligibility Criteria

Age 18 - 90 · Male Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a biopsy-proven diagnosis of prostate adenocarcinoma.